CARsgen presents positive long-term zevor-cel results at IMS meeting

CARsgen Therapeutics Holdings Limited (CARsgen) has disclosed updated long-term follow-up results for zevorcabtagene autoleucel (R&D code: CT053), an autologous BCMA CAR T-cell product. These findings were presented as a poster at the 22nd International Myeloma Society (IMS) Annual Meeting on September 17, 2025, in Toronto.

Zevorcabtagene autoleucel, a fully human, autologous BCMA CAR T-cell product, is designed for the treatment of multiple myeloma (MM). The product received NMPA approval on February 23, 2024, for adult patients with relapsed/refractory MM who had progressed after at least three prior lines of therapy.

In 2019, zevorcabtagene autoleucel was granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations by the U.S. FDA, highlighting its potential to address unmet medical needs in a serious or life-threatening condition.